In a real-world population of adults with migraine, the investigators would like to
investigate whether 50 mg diclofenac potassium is non-inferior to 75 mg rimegepant in terms
of pain freedom at 2 hours after drug intake.
The study design is a randomized, open-label, parallel-group, single-attack study with 50 mg
diclofenac potassium and 75 mg rimegepant. 645 patients with migraine with or without aura
according to the third edition of the International Classification of Headache Disorders
(ICHD-3) will be included.
Each subject will randomly be allocated to one treatment, and given 42 days to treat a single
qualifying migraine attack of moderate to severe intensity.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.